Patents by Inventor Eric D. Bischoff

Eric D. Bischoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and Pharmaceutical Compositions for Treatment of Anti-Estrogen Resistant Breast Cancer Using RXR Modulators
    Publication number: 20090093546
    Abstract: Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds that are modulators of Retinoid X Receptors are provide.
    Type: Application
    Filed: November 19, 2008
    Publication date: April 9, 2009
    Inventors: William W. Lamph, Eric D. Bischoff, Richard A. Heyman
  • Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR modulators
    Patent number: 7259188
    Abstract: Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds which are modulators of Retinoid X Receptors.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: August 21, 2007
    Assignee: Llgand Pharmaceuticals Incorporated
    Inventors: William W. Lamph, Eric D. Bischoff, Richard A. Heyman
  • Methods for affecting various diseases utilizing LXR compounds
    Patent number: 6924311
    Abstract: The present invention relates to methods for elevating high density lipoprotein (HDL) plasma levels, decreasing the absorption of dietary cholesterol in the intestine, decreasing the plasma level of low density lipoprotein (LDL), and increasing the conversion of cholesterol to bile acids, utilizing LXR? selective agonists, usually without elevating the plasma levels of triglycerides. Also provided are methods of using such agonists to treat metabolic diseases alone or in combination with other active agents. Also provided are methods for decreasing hyperglycemia and insulin resistance methods for treating type II diabetes, and methods for treating type II diabetes and reducing the cardiovascular complications of type II diabetes, utilizing an LXR agonist. Further provided are methods for treating obesity and methods for treating the complications of obesity including type II diabetes, cardiovascular disease, hyperlipidemia, and hypertension, administering an LXR?-selective antagonist.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: August 2, 2005
    Assignee: X-Ceptor Therapeutics, Inc.
    Inventors: Ira G. Schulman, Eric D. Bischoff, Rajendra K. Tangirala
  • Methods for affecting various diseases utilizing LXR compounds
    Publication number: 20030073614
    Abstract: The present invention relates to methods for elevating high density lipoprotein (HDL) plasma levels, decreasing the absorption of dietary cholesterol in the intestine, decreasing the plasma level of low density lipoprotein (LDL), and increasing the conversion of cholesterol to bile acids, utilizing LXR&bgr; selective agonists, usually without elevating the plasma levels of triglycerides. Also provided are methods of using such agonists to treat metabolic diseases alone or in combination with other active agents. Also provided are methods for decreasing hyperglycemia and insulin resistance methods for treating type II diabetes, and methods for treating type II diabetes and reducing the cardiovascular complications of type II diabetes, utilizing an LXR agonist. Further provided are methods for treating obesity and methods for treating the complications of obesity including type II diabetes, cardiovascular disease, hyperlipidemia, and hypertension, administering an LXR&agr;-selective antagonist.
    Type: Application
    Filed: October 17, 2001
    Publication date: April 17, 2003
    Inventors: Ira G. Schulman, Eric D. Bischoff, Rajendra K. Tangirala
  • Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR Modulators
    Publication number: 20030013766
    Abstract: Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds which are modulators of Retinoid X Receptors.
    Type: Application
    Filed: August 27, 2002
    Publication date: January 16, 2003
    Inventors: William W. Lamph, Eric D. Bischoff, Richard A. Heyman